Indacaterol Maleate (formerly known as QAB149; QAB-149; Onbrez Breezhale; arcapta neohaler; Onbrez), the maleate salt of indacaterol, is an approved anti-COPD (chronic obstructive pulmonary disease) drug acting as an ultra-long-acting β-adrenoceptor agonist developed by Novartis. β-adrenoceptor is activated with a pKi of 7.36 in. The FDA approved indacaterol in 2009 to treat chronic obstructive pulmonary disease (COPD). Using a dry powder inhaler, the aerosol formulation is administered. When Chinese hamster ovary cells are transfected with human β2 adrenoceptors and have a pEC50 of 8.06, indacaterol inhibits the production of cAMP.